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ENGLISH SUMMARY 
Opioids are often used in treatment of acute and chronic pain, but unfortunately lead 
to several unwanted side effects in the gastrointestinal (GI) tract. Opioid-induced 
constipation (OIC) is reported as the most common side effect, experienced by 40-
70% of patients taking opioids. The pathophysiology underlying OIC is complex and 
rely on activation of µ-opioid receptors in the enteric nervous system that have a 
negative impact on colonic motility, GI fluid secretion/absorption and sphincter 
function. OIC is normally treated with laxatives, although the efficacy is often low, 
and treatment may lead to additional GI symptoms. Recently, alternative treatment for 
OIC has become available. That includes co-administration of peripherally acting µ-
opioid receptor antagonists (PAMORA), which specifically treats the mechanisms 
underlying the pathophysiology of OIC. Measures of colonic function and motility 
can be difficult to obtain due to anatomy of the colon and the current available 
measurement techniques. The purpose of this PhD project was to establish objective 
measures of colonic function and apply them to test how colon physiology is affected 
by opioids and opioid-antagonists. 
     The first objective was to develop and validate methods to investigate detailed 
colonic motility, content and volume with objective measurement techniques 
including magnetic resonance imaging (MRI) and ingestible motility capsules (3D-
Transit). The second objective was to assess the effect of oxycodone treatment on 
detailed colonic motility, fecal dryness and volume using the newly established 
measurement techniques. The third objective was to assess the efficacy of the opioid-
antagonist naloxegol combined with oxycodone on detailed colonic motility.  
     Objective 1 was investigated in 45 healthy volunteers and 7 patients with known 
chronic diarrhea. Data were combined from three independent clinical trials to be used 
for development of measurement methods. It was possible to establish a method that 
could estimate colonic length and describe colonic motor patterns that moved a 
motility capsule at fast and slow velocities, at differing length and mostly antegrade, 
but also retrograde. Furthermore, colonic fecal volume and fecal dryness were 
described for each colonic segment using MRI. Objective 2 was investigated in 25 
healthy volunteers who were treated for five days with oxycodone or placebo in a 
double-blinded, randomized, crossover design. Oxycodone treatment effectively 
induced OIC symptoms including increased colonic transit time, increased colonic 
fecal volume and decreased stool water amount. Colonic motor patterns were slower 
during oxycodone treatment. Objective 3 included 24 healthy volunteers who were 
treated for six days with naloxegol combined with oxycodone or placebo combined 
with oxycodone in a double-blinded, randomized, cross-over design. Naloxegol 
effectively reversed most of the oxycodone-induced symptoms on colonic motor 
function including colonic transit time and made the motor patterns faster compared 
to oxycodone alone.  
     In conclusion, methods using motility capsules and MRI were developed and 
showed that oxycodone treatment affects colonic motor patterns and content. 
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Naloxegol reverses most of the induced changes in colonic motility. Despite 
limitations of study design, the proposed methods were useful to investigate the 
complex pathophysiology underlying OIC. Further validation of methods and 
comparison with e.g. high-resolution manometry may optimize methods to enable 
classification of more detailed motor patterns.  
  
IX 
DANSK RESUME 
Opioider som morfin, bliver ofte brugt i behandlingen af akutte og kroniske smerter, 
hvilket desværre medfører en række bivirkninger i mavetarmkanalen. Opioid-
induceret forstoppelse er den hyppigste bivirkning, og 40-70% af patienter i opioid-
behandling får forstoppelse. Patofysiologien bag forstoppelsen er kompleks og 
afhænger af aktivering af µ-opioid receptorer i det enteriske nervesystem, som har en 
negativ effekt på tyktarmens kontraktionsmønstre, sekretion, væskeabsorption og 
sfinkterfunktion. Opioid-induceret forstoppelse bliver normalt behandlet med 
laksantia. Denne behandling er ofte ineffektiv og bidrager ofte med yderligere 
bivirkninger i mavetarmkanalen. En nyere behandlingsmetode benytter perifert 
virkende µ-opioid antagonister, som specifikt behandler de mekanistiske forandringer 
i tarmvæggen forårsaget af opioidbehandlingen. Det kan være svært at måle på 
tyktarmens funktioner og kontraktionsmønstre pga. dens anatomiske lokalisering og 
begrænsninger af de nuværende metoder til at måle tarmfunktion. Formålet med dette 
ph.d.-projekt var at udvikle og etablere målemetoder til at måle på tyktarmsfunktion 
og anvende dem til at teste dens fysiologi under opioidbehandling og efterfølgende 
under behandling med opioid-antagonister.  
     Projektets første formål var at udvikle og validere objektive målemetoder til at 
undersøge tyktarmens kontraktionsmønstre, volumen og indhold ved brug af 
magnetisk resonans (MR) skanninger og motilitetskapsler (3D-Transit). Det andet 
formål var at bruge de nyudviklede metoder til at vurdere, hvordan behandling med 
opioidet oxycodon påvirker tyktarmens kontraktionsmønstre, tørhed og volumen af 
indhold. Det tredje formål var at vurdere, hvor effektivt opioid-antagonisten naloxegol 
kombineret med oxycodon kunne modvirke de opioid-inducerede ændringer i 
tyktarmens kontraktionsmønstre.  
     Første formål blev undersøgt i 45 raske frivillige og 7 patienter med kendt kronisk 
diarré. Data blev indsamlet i tre uafhængige kliniske forsøg og skulle anvendes til at 
udvikle målemetoderne. Det var muligt at etablere en metode, der kunne estimere 
længden af tyktarmen samt beskrive tyktarmens kontraktionsmønstre med en 
motilitetskapsel. Kapslen kunne måle hurtige og langsomme tarmbevægelser i 
forskellige længder, som kunne være enten forud- eller bagudrettet. Desuden kunne 
MR-skanninger bruges til at beskrive volumen og tørhed af tyktarmsindhold. Det 
andet formål blev undersøgt i 25 raske frivillige, som blev behandlet i fem dage med 
oxycodon eller placebo i et dobbeltblindet, randomiseret, overkrydsningsstudie. 
Behandling med oxycodon resulterede i symptomer i mavetarmkanalen. Transittid 
igennem tyktarmen og volumen af tyktarmsindhold var forøget, mens indholdet havde 
mindre vandindhold. Bevægelsesmønstrene i tyktarmen var langsommere under 
opioidbehandlingen sammenlignet med placebo. Det tredje formål blev undersøgt i 
24 raske frivillige, som blev behandlet i seks dage med opioidantagonisten naloxegol 
kombineret med oxycodon eller placebo kombineret med oxycodon i et 
dobbeltblindet, randomiseret, overkrydsningsstudie. Naloxegol ændrede de fleste af 
de opioid-inducerede forstyrrelser i tyktarmens bevægelsesmønstre tilbage mod 
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normalen. Behandlingen nedsatte transittiden og gjorde bevægelsesmønstrene 
hurtigere sammenlignet med oxycodonbehandlingen.  
     Den nye metode baseret på målinger med motilitetskapsler og MR-skanninger 
viste at oxycodon-behandling påvirker tyktarmens bevægelsesmønstre og 
tarmindhold. Naloxegol modvirker de fleste af bivirkningerne. Til trods for 
begrænsninger med det valgte studiedesign, kunne de foreslåede metoder undersøge 
den komplekse patofysiologi bag opioid-induceret forstoppelse. Et fremtidigt 
valideringsstudie af de anvendte metoder, kunne kombinere undersøgelserne med 
f.eks. højopløsnings-manometri, hvorefter det burde være muligt at optimere 
metoderne til at klassificere tarmens bevægelsesmønstre i endnu højere detaljegrad 
end i dette ph.d.-studie.  
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CHAPTER 1. INTRODUCTION  
Opioids are among the most commonly prescribed analgesics for moderate and severe 
acute and chronic pain. They are one among the potent treatments used for pain 
management and there has been a recent rise in opiate consumption leading to more 
frequently reported side effects.1 Approximately 3-5% of all inhabitants in Denmark 
use opioids.2 Unfortunately, opioids are associated with multiple adverse effects that 
counteracts their analgesic effect. The opioids bind to specific receptors within the 
central nervous system (CNS), whereby they decrease firing of nerves caused by pain 
stimuli and ultimately decrease the pain. The enteric nervous system (ENS) found in 
the gastrointestinal (GI) tract also contains opioid receptors, where the binding of 
opioids happens as well, although with unwanted side-effects. In the bowel wall, 
opioids binds to opioid µ-receptors,3,4 and affect gut motility, secretion and sphincter 
function.5 This causes a cluster of GI symptoms referred to as opioid-induced bowel 
dysfunction (OIBD). OIBD embraces gastroesophageal reflux, abdominal discomfort, 
vomiting, bloating, rumbling and infrequent, incomplete or difficult evacuation.6 The 
most common adverse effect of opioid treatment is opioid-induced constipation 
(OIC), which 40-70% of patients taking opioids suffer from.6,7 Unfortunately for the 
patients as well as for health care and social economics, OIC has been associated with 
reduced work productivity and quality of life.8,9 The side-effects of opioid treatment 
are cumulative. It is well-known that colonic transit time increases during opioid use,10 
and a prolonged colonic transit increases passive water absorption leading to drier 
stools that ultimately contributes to OIC.11 Opioids, however, also directly affect 
secretion of water to the gut. When investigating the pathophysiology behind OIC it 
is important to factor in knowledge of colonic water content and fecal volume, which 
helps to investigate colonic secretion and how the opioid treatment affects it.12 
Conventional laxatives are the recommended treatment for OIC.13 Unfortunately, 
laxatives do not always provide an adequate effect on the OIC,14 and they are also 
associated with a number of adverse effects like bloating, abdominal distension and 
gastroesophageal reflux.15 Several opioid receptor antagonists developed specifically 
for targeting the pathophysiology of OIC (i.e., does not cross the blood-brain barrier) 
have been introduced within the last decade,16,17 but studies investigating their effect 
on colonic volume, secretion and water absorption are lacking. As of now, it is thought 
that opioids reduce gut water secretion by inactivating chloride channels in the gut 
mucosa, which disrupts the osmotic gradient across the gut lumen.18 However, it is 
difficult to assess the effect of opioids on gut water content and fecal volume in 
clinical practice. We know that opioid receptor agonists have an impact on both 
excitatory and inhibitory activity, and they can activate the interstitial cell–muscle 
network. Hence, their effects on GI motility and secretion may be complex.19 Most of 
our current knowledge is obtained from isolated muscle strips or preclinical studies, 
why it remains to be determined how opioids affect the colon in vivo, and whether 
opioids lengthen transit by causing dyscoordinated peristalsis or changes the motor 
pattern.20 Regardless, the pathophysiology behind OIC needs further investigations. 
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CHAPTER 2. BACKGROUND 
2.1. COLONIC ANATOMY AND PHYSIOLOGY 
The large intestine, also known as the colon, is the last part of the GI tract starting 
after the ileum and ending at the rectum. The colonic organ is about 1 to 1.5 meter 
long and has a width of 7.5 cm, however the size and shape of individual segments 
and the total length have very high variation between individuals.21–23 Especially the 
s-shaped sigmoid colon can change its shape and often folds up towards the transverse 
colon (Figure 1). The primary functions of the large intestine are to reabsorb water, 
absorb vitamins, and compress indigestible materials in preparation for defecation. 
Only 10% of the total GI nutrient absorption occurs in the colon.23 The cecum is the 
most proximal part of the colon, where the fecal material is mixed and awaits further 
propagation. During propagation towards the rectum, most of the water content is 
absorbed through the gut wall. Each day 1400 mL of intestinal content enters the 
cecum from the ileum (small intestine) and only 150 mL of feces is evacuated.23 The 
average composition of feces is 75% water, 5% bacteria, and a mixture of remains of 
epithelial cells, indigestible material and inorganic matter. Colonic content is moved 
towards the rectum by contractions of the circular muscle layer in the gut wall. 
1450 mL water
absorbed per day
Ascending colon
(200 mL volume)
Descending colon
(150 mL volume)
Transverse colon
(200 mL volume)
Sigmoid colon
(250 mL volume)Rectum
Cecum
Hepatic flexure Splenic flexure
Sigmoid flexure
Ileum
150 mL 
evacuated per day
1400 mL material 
enters per day
200 mL  colonic
mucous secretions
per day
Figure 1. The anatomy of the large intestine and typical volumes for colonic segments, inputs 
and outputs. Absorption of water is marked with blue arrows. 
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Colonic contractions are collectively referred to as colonic motility which represents 
the complex mechanisms that transports the fecal material through the large intestine.   
2.2. THE ENTERIC NERVOUS SYSTEM 
The ENS plays a dominant role in GI physiology. The GI tract is innervated through 
an extrinsic component via the CNS and an intrinsic component mainly inside the 
bowel wall via the ENS. Even if parts of the GI tract is isolated from the CNS, motor 
activity is still observed.24 GI function is mostly controlled through parasympathetic 
pathways, that increases secretion, peristalsis and vasodilation. In contrast, the 
sympathetic pathways reduces peristalsis and causes vasoconstriction.25 The motor 
activity in the gut is controlled and monitored trough the 200-600 million neurons in 
the ENS, that collectively forms a complex network of motor neurons, interneurons 
and sensory neurons.25 The mechanical modulation and progression of luminal 
content are performed by the longitudinal and circular muscle fibers in the gut wall. 
In general, the nerves in ENS can be divided in the submucosal plexus and the 
myenteric plexus (Figure 2). Secretion and absorption are controlled by the 
submucosal plexus (located close to the intestinal epithelium), while the myenteric 
plexus mainly is responsible for controlling GI motor activity (located between the 
two muscle layers). The µ-receptor is the most expressed opioid receptor in the human 
ENS, and it is localized in both the myenteric and submucosal plexuses. The µ-
receptors are involved in the control of GI motility and are activated by the 
endogenous ligands endorphins, dynorphins and enkephalins.26 The opioid receptors 
(also including  κ- and δ-receptors) lead to reduced neurotransmitter release and 
neuronal excitability.27 Binding of opioid agonists to the receptors activate potassium 
Figure 2. The enteric nervous system alongside the gastrointestinal tract. 
Propulsion
Gut lumen
Luminal contentMuscle contraction
Intestinal epithelium
Submucosal plexus
Myenteric plexus
Opioid receptor
Longitudinal muscle
Circular muscle
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channels and inhibit calcium channels, which leads to decreased release of 
neurotransmitter and hyperpolarization, ultimately reducing the probability for firing 
of action potentials.28 
2.3. COLONIC MOTILITY 
 “Colonic motor patterns are one of the most variable and unpredictable 
phenomena in organisms.”  
This quote from SK. Sarna, 2010 clearly underlines the difficulties in understanding 
the human colon physiology.29 Throughout the colon, contraction frequency and 
amplitude vary not only diurnally, but also according to gender, physical exercise, 
meals, and psychological stress.29 Despite this, there has for many years been focus 
on investigating colonic motility, especially in relevance to pathophysiology of 
various GI diseases and unwanted side-effects to pharmacological interventions like 
opioid treatment.  
Peristalsis 
Most of colonic motor activity is coordinated contractions and relaxations of the 
intestinal lamina muscularis called peristalsis.30 The contractions have the purpose of 
moving luminal contents through the gut and mixing it with secreted fluids. Three 
different contraction types perform most of the known colonic motility functions:29  
1. Rhythmic phasic contractions mix the luminal content and cause a slow 
progressive propulsion.  
2. Tonic contractions aid the motor function of the rhythmic phasic 
contractions.  
3. Mass movements are produced by the giant migrating contractions that 
occurs only few times per day. The distance of propagation and contraction 
amplitude during a mass movement are much larger than in the slower 
rhythmic phasic contractions. The large contractions of the smooth muscle 
cells increase the intraluminal pressure, thereby called high-amplitude 
propagating sequences (HAPS).31  
These contraction types result in different colonic motility patterns (Figure 3). The 
colonic motility patterns shown in the figure are recently deducted from high-
resolution manometry (HRM) studies,32,33 and additional motor patterns exist beside 
these, although these represent the most essential movements. Much alike the mass 
movements, the long single propagating motor pattern progresses throughout the 
colon and at faster velocity, although with much lower contraction amplitude.32 A 
cyclic propagating motor pattern has also been described and progresses either 
antegrade or retrograde, and will continue to make contractions at the same location 
to mix the content in a cycle lasting minutes.32  
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Regulation of colonic motility 
Colonic motility is very complex, and it is regulated both by internal and external 
signals. The colon has a contraction frequency of approximately 3-6 contractions per 
minute (CPM). Inhibitory neurons in the ENS determine the length and duration of 
the contractions and they can even decrease the pace of slow waves, which produces 
the smooth muscle contractions.34 
Regulation due to luminal content. 
The neurons in the ENS have important mechanosensitive nerve endings in the 
smooth muscles in the gut wall, which are able to coordinate oral contraction and anal 
relaxation making the luminal content move forward.35 Due to these mechanosensitive 
nerve endings, peristalsis can be triggered by mechanical distension of the gut.30 The 
neurological pathways represent a neuromechanical loop that is responsible for 
propulsion related to the consistency of the luminal content. Hence, the complex 
mechanisms underlying colonic peristalsis are able to adjust motor activity 
accordingly and make fluid content progress faster than solid content.35  
 
Regulation by external signals.  
The colonic contractions are regulated by several extrinsic factors including CNS, 
hormones, autonomic neurons, stress mediators, and inflammatory mediators.29 
Furthermore, colonic motility is triggered by early awakening and ingestion of meals 
and coffee due to the gastrocolic response.32,36,37 Analgesic treatment with opioids 
likewise affects colonic motility by occupying the µ-receptors in the ENS and block 
the firing of action potentials in the bowel wall, ultimately leading to reduced motility 
and constipation. The pathophysiology underlying OIC is elaborated in the following 
section. 
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Figure 3. Colonic propulsive motor patterns. 
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2.4. OPIOID-INDUCED CONSTIPATION 
Treatment with opioids often induce several unwanted GI side-effects that may reduce 
quality of life and burden daily activities and make patients discontinue treatment or 
reduce the opioid dose.38,39 As much as one third of patients feel the need of decreasing 
treatment dose or discontinue treatment due to side-effects.40 Long term constipation 
in relation to opioid treatment may furthermore induce risk of ileus, colonic distension 
and gut perforation, which all are associated with increased mortality.41 The 
pathophysiology underlying OIC is complex and both gut secretion and motility are 
affected during treatment with opioids.  
Opioids and gut secretion 
Gut water secretion is reduced during opioid treatment due to inactivated chloride 
channels in the gut mucosa, which causes a disruption in the osmotic gradient.18 The 
decrease in secretion of intestinal fluids leads to drier and harder stools. Subsequently, 
motility is dependent on luminal content and volume, why a change in consistence 
and volume affects peristalsis.25,35 
Opioids and colonic motility 
Opioid treatment increases the resting contractile tone of the circular muscle layer in 
the gut wall.42,43 This increases non-propulsive phasic contractions of the longitudinal 
muscle layer and thereby reduces propulsive motility.5,44 Furthermore, opioids may 
also cause dysregulated motility through a suppression of the neurotransmitter 
acetylcholine via CNS-stimulated sympathetic overflow in the gut.45 Consequently, 
colonic transit is prolonged during opioid use,10,46 which prolongs time for passive 
absorption of fluids during colonic passage and results in dryer and harder stools. The 
changed contractile activity manifests as bloating, abdominal cramps and 
constipation. Most of our knowledge on opioids’ effect on colonic motility is obtained 
from preclinical or ex-vivo studies, why it is yet to be determined how opioids affect 
the in-vivo human colon. It is important to establish whether opioids prolong transit 
by reducing the number of mass movement or by inducing uncoordinated peristalsis. 
Treatment of OIC 
It is recommended to perform physical activity and increase daily fiber intake to 
decrease constipation severity. However, only little evidence proof an effect of these 
lifestyle changes.27 The mainstay first-line therapy for OIC is laxatives, but they have 
no effect on the underlying mechanisms.9 Laxatives increase the osmotic gradient, 
which increases water content (and volume) in the colon leading to a stimulation of 
the smooth muscles in the colon wall. Consequently, less than half of opioid treated 
patients using laxatives report an acceptable therapeutic effect, and furthermore, many 
patients still have GI symptoms even with the use of two or more types of laxatives.8,47 
Laxative treatment has also been shown to induce several other symptoms like 
abdominal pain, gas, bloating, and gastro-esophageal reflux, why other treatments are 
warranted.48 Peripherally acting µ-opioid receptor antagonists (PAMORAs) are a new 
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group of treatments for opioid-induced GI side effects. They specifically block 
periphery µ-opioid receptors (in the gut wall) and preserve the wanted analgesic effect 
(Figure 4).49 Naloxegol is a PAMORA, and is the OIC treatment included for 
investigation in this thesis. It is a derivative of naloxone and cannot enter the CNS 
through the blood-brain barrier mainly due to its large molecule size. Naloxegol has 
been shown to decrease GI symptoms and increase weekly stool frequency.50,51 
2.5. MEASUREMENTS OF COLONIC MOTILITY 
Measurements of colonic motility can be difficult to perform due to the colon anatomy 
and its location. Although, during the recent years there has been technology advances 
in several different modalities including magnetic resonance imaging (MRI), HRM, 
and motility capsules.32,36,52 Several techniques are able to perform measurements 
inside the colon; however, most of our current knowledge on colonic motility and 
motor patterns has been obtained from colonic HRM studies.53 This is mainly due to 
the impressive research by Phil Dinning and his colleagues, who have performed a 
long number of clinical studies in the past years including studies of proximal pressure 
waves,54 patients with constipation,33,55–57 patients with colonic motor disorders,58 the 
investigation of meal response,32 bowel preparation,59 and the rectosigmoid brake.60 
The current gold-standard for direct assessment of colonic motor function is HRM.61 
Figure 4. The effect of opioids and naloxegol on gut motility. Opioids occupy the µ-opioid 
receptors and decrease effective propulsion. Naloxegol blocks the µ-opioid receptors and 
decrease gastrointestinal side effects. Abbreviation: ENS, enteric nervous system. 
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HRM provide the best available insight into colonic motility, however recordings are 
obtained with a catheter placed during colonoscopy. This requires a highly trained 
investigator, and the colon needs to be empty, which can disturb normal physiology. 
Furthermore, investigations often last more than 8 hours, and the technique is mainly 
used in pediatrics. In clinical practice, colonic motility is indirectly assessed by 
investigating transit time measured with scintigraphy and radiopaque markers.62,63 
MRI holds the potential to a series of interesting measures of gut motility that does 
not involve unpleasant invasive procedures. It has recently been used to assess 
proximal colonic motility and to describe the luminal content of the colon.52,64–67 
Beside the many applications of MRI, scanner technology develop fast, and most 
hospitals have access to MRI equipment, why this methodology is especially 
interesting to follow in the near future.   
     Motility capsules represent another and more ambulatory approach to measure 
colonic transit and motility. The wireless motility capsule (WMC, Given Imaging, 
Israel) allows estimates of regional transit times through the stomach, small bowel 
and colon. It also provides intraluminal pressure readings allowing for indirect 
assessment of GI motility.68 The system does however, not determine the precise 
capsule position within the colon, which is needed for description of progression 
patterns.69 The Motilis 3D-Transit system (Motilis Medica SA, Lausanne, 
Switzerland) determines the position of ingestible electromagnetic capsules 
throughout GI passage, making measurements of regional transit times possible.70 
Further analysis of the capsule position within the colon also allows for estimations 
of capsule movement. This is unfortunately, not possible to do using the native Motilis 
analysis software, and the development of such methodology is described in this thesis 
and was part of Paper I and Paper II.20,71 Description of colonic movements cannot be 
performed with other ambulatory systems than the 3D-Transit system. An overview 
of colonic measurement methods and their advantages is shown in Table 1. 
DETAILED MOTILITY AND FUNCTION OF THE OPIOID-AFFECTED COLON 
24 
Table 1. Summary of current methods to assess colonic content, transit and motility. Inspired 
by the review by Grønlund et al., 2017.75 Abbreviations: WMC, wireless motility capsule, MRI, 
magnetic resonance imaging; HRM, high-resolution manometry. 
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Scintigraphy             Parkman et al., 2014 (62) 
Radiopaque 
markers 
              Metcalf et al., 1987 (63) 
WMC             Wang et al., 2015 (72) 
Farmer et al., 2017 (73) 
3D-Transit             Haase et al., 2014 (70) 
Mark et al., 2018 (20) 
MRI             Hoad et al., 2016 (52) 
Hoad et al., 2016 (74) 
Murray et al., 2017 (66)  
HRM             Dinning et al., 2014 (32) 
Dinning et al., 2015 (33) 
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CHAPTER 3. HYPOTHESES & AIMS 
To establish reliable measurement techniques, the first objective of this thesis was to 
develop and validate methods to investigate colonic motility and assess colonic 
content and volume. Thus, it was hypothesized that measurement methods could be 
established, and they were reliable between days. This objective was studied in 
healthy volunteers and in a small cross-sectional study of patients with chronic 
diarrhea that was included to validate the measures of colonic motility.  
The second objective was to assess the effect of oxycodone on colonic motility and 
content, and it was hypothesized that oxycodone would decrease colonic motility, 
induce dyscoordinated motility, increase fecal volume and increase stool dryness. 
This was studied in healthy volunteers who were treated with oxycodone to induce 
constipation in an experimental modelled setting. Measurements were performed 
during close-to-normal days, in two periods with either oxycodone treatment or 
placebo. 
The third objective was to assess the effect of an opioid-antagonist (naloxegol) 
combined with oxycodone on colonic motility. Lastly, it was hypothesized that 
naloxegol in co-administration with opioids would normalize colonic motility. This 
was studied in healthy volunteers in an experimental setting. Measurements were 
performed during close-to-normal days, in two periods with either naloxegol co-
administered with oxycodone or placebo co-administered with oxycodone. 
The thesis is based on four papers (Paper I, II, and III are peer-reviewed) that compile 
data from four clinical trials. Study aims are shown in Figure 5. 
 
Aim 1 Aim 2 Aim 3 Aim 5
Validation of 
methods
Clinical application
Paper IIPaper I Paper IVPaper III
Aim 6Aim 4
Paper III
Oxycodone vs. 
placebo
Naloxegol+oxycodone 
vs. placebo+oxycodone
Paper IV
Technical development
Figure 5. Overview of study aims and papers in the PhD thesis. 
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Aims 
 
1. To develop, test reliability and validate a method to measure colonic length 
using the 3D-Transit system (Paper I). 
 
2. To develop, test reliability and validate a method to measure detailed colonic 
motility using the 3D-Transit system (Paper II). 
 
3. To develop and test reliability of a method to measure colonic fecal volume 
and colonic fecal dryness using MRI (Paper III). 
 
4. To evaluate how oxycodone treatment, compared to placebo, affects colonic 
fecal volume and colonic fecal dryness (Paper III). 
 
5. To evaluate how oxycodone treatment, compared to placebo, affects detailed 
colonic motility (Paper IV). 
 
6. To evaluate how the opioid antagonist naloxegol co-administered with 
oxycodone, compared to placebo co-administered with oxycodone, affects 
detailed colonic motility (Paper IV).  
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CHAPTER 4. MATERIALS & METHODS 
Colonic motility plays a dominant role in the cause of OIC, why the large intestine is 
a key segment to investigate in assessment of GI tract function. Research of the 
mechanisms behind the pathophysiology in the colon is therefore highly needed. To 
enlighten this specific subject, colonic function and motility were investigated using 
data recorded in four clinical trials, which are described in the following section.   
4.1. STUDY DESIGN 
The four included clinical trials all include measurements using the 3D-Transit 
system, while only trial 3 includes MRI. Data from the four trials have been combined 
in the four included papers. See an overview of the study design in Figure 6 and a 
description of the four included clinical trials in Table 2. Detailed descriptions are 
listed in the following sections. All trials were carried out in accordance with the 
principles of the European Community rules of Good Clinical Practice (GCP) and the 
Declaration of Helsinki. Written informed consent was obtained from all participants. 
Trial 1 and 2 were carried out at the Neurogastroenterology Unit, Department of 
Hepatology and Gastroenterology, Aarhus University Hospital, Denmark, while trial 
3 and 4 were carried out at the research facilities of Mech-Sense, Aalborg University 
Trial 4
HV
(n=24)
Oxycodone + 
Naloxegol
Oxycodone + 
Placebo
Oxycodone + 
Naloxegol
Oxycodone + 
Placebo
Wash-out
Period 1
Period 2
Trial 3
HV
(n=25)
Oxycodone Placebo
PlaceboOxycodone
Trial 2
CD
(n=7)
Trial 1
HV
(n=20)
HV (Placebo)
(n=25)
HV
(n=45)
Paper I Paper II Paper III Paper IV
HV (placebo)
3D-Transit 3D-TransitMRI
3D-Transit
and MRI
Figure 6. Overview of data from the four included clinical trials. Paper I combines data from 
trial 1 and 3 with the objective of developing and validating methods used to estimate colonic 
length. Paper II combines data from trial 1, 2 and 3 with the objective of developing and 
validating methods to describe detailed colonic motility. Paper III includes data from trial 3 to 
describe colonic content during opioid treatment. Paper IV includes data from trial 3 and 4 to 
describe detailed colonic motility during opioid and opioid antagonist treatments. 
Abbreviations: CD, patients with chronic diarrhea; HV, healthy volunteer; MRI, magnetic 
resonance imaging.  
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Hospital, Department of Gastroenterology & Hepatology, Aalborg, Denmark. The 
clinical trials did also include other end-points that are not part of the included papers 
and thereby not presented in this thesis.10,70,76–79 Development and validation of 
methods were performed using data from trial 1, 2, and 3, while the investigations of 
colonic function and detailed motility during pharmacological interventions were 
performed using data from trial 3 and 4.  
Table 2. Overview of the four trials included in the thesis. Abbreviations: no, number; HV, 
healthy volunteers; CD, patients with chronic diarrhea; MRI, magnetic resonance imaging.  
Trial 1 
Trial 1 included 3D-Transit recordings of 20 healthy volunteers studied with three 
capsules on two consecutive days (Figure 7). All healthy volunteers swallowed a 
capsule on completion of a standardized meal at 08:00. They also swallowed capsules 
at 18:30 on day 1 and 08:00 on the morning of day 2. Recordings continued until the 
capsules were evacuated. 
 Subjects Study 
design 
Period 
length 
Treatment Included 
measures 
Ethical 
reference 
no. 
Danish 
Health and 
Medicines 
Authority 
Research 
facility 
Trial 1. 
Paper: I, II 
Aim: 1,2 
HV 
(n=20) 
Cross-
sectional 
1 x 5 
days 
None 3D-Transit M-2010-
0267 
2011-
123594 
Aarhus 
University 
Hospital, DK 
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Paper: II 
Aim: 2 
CD 
(n=7) 
Cross-
sectional 
1 x 5 
days 
None 3D-Transit - 2012-
00393927 
Aarhus 
University 
Hospital, DK 
Trial 3 
Paper: I-III 
Aim: 1-5 
HV 
(n=25) 
Cross-
over 
2 x 5 
days 
Oxycodone 
vs placebo 
3D-Transit 
and MRI 
N-2013-
0030 
2013-   
070299 
Aalborg 
University 
Hospital, DK 
Trial 4  
Paper: IV  
Aim: 6 
HV 
(n=24) 
Cross-
over 
2 x 6 
days 
Oxycodone+ 
naloxegol vs. 
oxycodone+ 
placebo 
3D-Transit  N-2015-
0014 
2015-
021429 
Aalborg 
University 
Hospital, DK 
Day 1 Day 2 Day 3 Day 4
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3D-Transit
start
3D-Transit
end
Capsule 1 
ingested
Standardised meals
Capsule 2 
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14:00
16:00
Standardised meals
Standardised meals
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Figure 7. Overview on 3D-Transit capsule and meal ingestion times in trial 1. 
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Trial 2 
Seven patients with pathology verified metastatic neuroendocrine tumors and 
carcinoid diarrhea were studied with one 3D-Transit capsule swallowed in the 
morning on completion of a standardized meal. The patients stayed at the hospital 
during the examination (Figure 8).  
Trial 3 
Trial 3 included 3D-Transit recordings and MRI scans in 25 healthy volunteers. 
Participants were studied in two study periods of five days each, where they were 
treated with either oxycodone or matching placebo (Figure 9). MRI was performed 
before first treatment dose on day 1 and after last dose on day 5. Capsules were 
ingested after the MRI scan on the first study day after a standardized meal.  
Trial 4 
Twenty-four healthy volunteers were studied with 3D-Transit in two study periods of 
six days each. They were treated with either combined oxycodone plus naloxegol or 
combined oxycodone plus placebo (Figure 10). 3D-Transit capsules were ingested on 
the second study day in each period after a standardized meal.  
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Day 2 Day 3 Day 4
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MRI
Evening
Morning
5 mg oxycodone
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10 mg oxycodone
or placebo
3D-Transit
start
3D-Transit
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10 mg oxycodone
or placebo
10 mg oxycodone
or placebo
10 mg oxycodone
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10 mg oxycodone
or placebo
10 mg oxycodone
or placebo
10 mg oxycodone
or placebo
Figure 9. Overview on one five-day treatment period in trial 3.  
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Figure 10. Overview on one six-day treatment period in trial 4. 
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Figure 8. Overview on 3D-Transit recording time line in trial 2. 
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4.2. THE 3D-TRANSIT SYSTEM 
Colonic motility is quantified using the 3D-Transit system (Motilis Medica SA, 
Lausanne, Switzerland, www.motilis.com).20,70,71,79 The system consists of a detector 
plate worn in an abdominal belt that tracks small ingestible electromagnetic capsules, 
through their GI passage (Figure 11). The system can record data from passage 
through the stomach, small intestine and the colon. This thesis only contains data 
recorded in the colon, why examinations of other parts of the GI tract will not be 
discussed. The capsules emit an electromagnetic field that is tracked by four sensors 
inside the detector plate and the capsule battery allows for approximately 5 days 
recording with a 5 Hz sampling frequency. Additionally, breathing is recorded with a 
respiratory chest-worn belt and accelerations of the detector are recorded with an 
accelerometer. These data are useful when assessing data quality. The 3D-Transit 
system has previous been used to report segmental GI transit times,10,70,79–81 however 
an earlier version of the capsule system (MTS-1) was used to describe and quantify 
colonic motility.36 The MTS-1 version of the capsule system relied on a permanent 
magnet and only allowed for stationary recordings, where the subject was positioned 
in a wooden bed at the research facility.82–85 The resulting colonic motility data 
reported by Hiroz et al., 2009 were unique, however the system had limited 
applicability due to its non-ambulatory nature.36 The methods used to analyze the 
colonic recordings were never translated from the older version, why that specific task 
was included in the current thesis. 
Figure 11. Overview of elements in the 3D-Transit system. A) Capsule size. Each capsule has 
a density of 1.6 g/cm3. B) The detector plate is worn in an abdominal belt and tracks the 
capsules through their gastrointestinal passage. The plate is powered by an external battery, 
and breathing is recorded from the respiratory belt. C) The capsules emit an electromagnetic 
field that can be translated into positional data. 
21 mm
8 mm
The 3D-Transit capsule Up to 3 capsules can be tracked simultanouslyThe 3D-Transit detector belt
A B C
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4.2.1.  ANALYSIS PIPELINE FOR COLONIC MOTILITY 
A five-step analysis pipeline for colonic motility analysis was set up (Figure 12). The 
following sections will shortly present each step that was performed before 
quantification of capsule movement was possible. 
Step 1: Locating colonic data 
Recordings in the large intestine were located in the native 3D-Transit software using 
a previous proposed procedure that locates a decline in bowel wall contraction 
frequency (represented by capsule rotations) from approximately 10 CPM in the ileum 
to approximately 3 CPM in the cecum, along with the capsule located in the lower left 
quadrant in the frontal view of the recording (Figure 13). This approach has been used 
in all previous studies using the 3D-Transit system.10,70,77,79–81,86,87 Colonic data was 
then exported for further analysis. 
Step 2: Clean data 
The 3D-Transit system records capsule progression in the gut. However, as the system 
is worn throughout the day at home during normal activities some problems with data 
quality arises. The detector is placed in a tight belt around the abdomen, but the belt 
can move itself in relation to the body. Capsule position is calculated in relation to the 
detector, why movements of the detector can look like capsule movements and 
potentially will be falsely classified as GI movements. The events causing these 
problems could be e.g. physical activity like running and fast posture changes. 
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Figure 13: The 3D-Transit software. Capsule passage through the ileocecal valve was located 
as a drop in contraction frequency (left) and a position in the lower abdomen (middle). The 
white vertical line (right) marks the capsule passage seen as a change in the capsule rotations 
(Φ and θ) and position (X, Y, Z). Abbreviations: CPM, contractions per minute. 
Figure 12: The five steps in the analysis of 3D-Transit data.  
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Furthermore, electronical interference from larger electronical devices could cause 
data loss. In order to assess data quality and remove artifacts from recordings, a 
graphical user interface (GUI) was implemented in MATLAB (MathWorks Inc, 
Natick, MA, USA) version R2016a (Figure 14 and Figure 15). Data was 
Figure 14. Graphical user interface for data cleaning. An algorithm finds a long movement 
that moves the capsule from the ascending colon and across the transverse colon. The 
movement is shown with dashed lines in a time and position plot (A) and with red color in a 
frontal plot of the X, and Y positional data (B). 
 
Figure 15. Marking of an artefact. (A) Time and position plot. The artifact is caused by a 
change in position (from posture changes) during nighttime. (B) Time and acceleration plot. 
The acceleration of the detector plate helps to separate real capsule movements from 
movements of the detector plate. The change in acceleration in X, Y and Z direction are aligned 
with the position data. (C) Frontal plot of X and Y position. The capsule ends up at the same 
position after the 20 minutes marked artifact. The artifacts can look like real GI movements, 
and they can be difficult to classify without the acceleration information. 
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automatically assessed and periods with bad data quality were excluded using the 
implemented GUI. The parameters used for this task were 1) high variation in capsule 
position, 2) high acceleration of the detector plate, and 3) low signal strength. Then 
an algorithm located all movements of the capsule (in relation to the detector) that 
were more than 4 cm with an average velocity of 4 cm in any direction. Approximately 
90% of these located movements are artifacts and in the current analysis pipeline, they 
need manual assessment of being real GI movement or not. In Figure 14 and Figure 
15 a GI movement and an artifact are shown. The GUI presents the located movements 
one at a time, and the observer is prompted to discard the artifacts, a task lasting 
approximately 20 minutes for a normal length dataset.  
Step 3: Visualization of capsule position 
After cleaning the capsule position data from artifacts, the data is down-sampled to 
allow for easier visualization and analysis. Two principles were applied to allow for 
visualization of both slow and fast capsule movements, 1) the distance from one 
datapoint to the next should not exceed 5 mm, 2) the time between one datapoint to 
the next should not exceed 3 minutes (Figure 16). These parameters represented data 
well and were close to what was used in the previous version of the system.36 Changes 
in the parameters will slightly change the analysis outcome. After visualization of data 
in the GUI, it is possible to extract the time points for when the capsule was in the 
hepatic flexure, in the splenic flexure, and in the sigmoid flexure. Thereby, segmental 
colonic transit times for the cecum/ascending-, transverse-, descending- and 
rectosigmoid colon are found. 
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Figure 16. Visualization of the colonic passage. 3D positional data has been down-sampled 
to show a datapoint for either 5 mm progression or 3 minutes with no movement (blue dots). 
Each hour of progression is marked with a red circle and an Arabic number. Segmental 
landmarks are placed at the hepatic flexure, splenic flexure and sigmoid flexure.  
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Step 4: Centerline of the colon 
A centerline through the colon was estimated with the purpose of having an 
anatomical guidance to compare capsule movement direction with. The line was 
estimated using an algorithm like the one used in the visualization of data. The 
principles were: 1) the distance from one datapoint to the next should not exceed 5 
mm, 2) the next data point should be nearer the next landmark (i.e. the hepatic flexure, 
the splenic flexure, sigmoid flexure, end of recording) than the previous. The time 
between points are not relevant in this estimation. The algorithm needs manual 
evaluation and adjustments if the dataset includes bad data points that is missed in 
previous steps. Lastly, the line is low pass filtered (2nd order Butterworth filter with a 
cut off at 0.05 Hz) to adjust for respiratory artifacts. The length of the estimated 
centerline now represents the antegrade passage of the capsule through the colon, 
which is used as the length of the colon in the following calculation of capsule 
displacements (Figure 17). The anatomy of the colon can be reproduced with a high 
spatial resolution using MRI. In trial 3 the healthy volunteers underwent MRI 
examinations the same day that 3D-Transit recordings were started. The colonic 
volume was segmented on each dataset, and a 3D topological skeleton algorithm was 
applied to the colonic segmentation masks and the medial path of each volume was 
extracted. The lengths of the estimated colonic centerlines were validated using two 
approaches (Paper I);71 1) compare estimated lengths against MRI segmentations in 
the same subjects, and 2) compare length between recordings performed on two 
consecutive days in the same subjects.  
Figure 17. A centerline representing colon anatomy is produced. The shown centerline is 150 
cm and it is used in the analysis of capsule movement. 
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Step 5: Quantify motility 
Capsule movements relative to the colonic centerline were calculated by projecting 
the 3D-postion data onto the line (Figure 18). Movements were located and classified 
according to length of displacement, velocity and direction of the movement. The 
applied parameters were inspired by the study by Hiroz et al., 2009,36 and can be seen 
in Table 3. To validate the proposed method to investigate colonic motility (Paper II), 
two approaches were used: 1) Compare recordings for the same subjects on two 
consecutive days, and 2) compare motility measures of a healthy group with patients 
who had known chronic diarrhea. 
 
Movement 
pattern 
Displacement 
upper limit  
Displacement 
lower limit  
Mean velocity 
upper limit 
Mean velocity 
lower limit 
Mass movement - >10 cm - >10 cm/min 
Fast antegrade <10 cm >4 cm - >4 cm/min 
Slow antegrade - >4 cm <4 cm/min >4 cm/hour 
Fast retrograde - <-4 cm - >4 cm/min 
Slow retrograde - <-4 cm <4 cm/min >4 cm/hour 
Table 3. The five identified colonic movement patterns. 
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Figure 18. Quantification of colonic motility. A) Positional data are projected onto the colon 
centerline at the point with lowest 3-dimensional distance between line and data point. B) 
Capsule movements relative to the centerline are located and visualized as time vs. colonic 
progression. Red lines represent fast movements and blue lines represent slow movements.  
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4.3. MRI-BASED MEASUREMENTS 
Colonic content was assessed using an MRI-based method (Paper III) written in 
MATLAB version R2013b. The method was firstly introduced in the study by 
Sandberg et al., 2015,88 and has previous been used to quantify colonic volumes.76–78 
The method has been further developed in the current thesis and now allows for 
analysis of content.  
4.3.1. ANALYSIS PIPELINE FOR MRI MEASURES 
Fecal volumes and stool dryness were estimated in four steps and will be shortly 
described in the following sections (Figure 19).  
Step 1: Magnetic Resonance Imaging 
Subjects were scanned using a 1.5T GE Discovery MR450 System (GE Healthcare, 
Milwaukee, WI, USA). Experiments included two coronal image series of the 
abdomen: 1) a T2-weighted single shot fast spin echo scan and 2) a T1-weighted 
Dixon-type liver accelerated volume acquisition (LAVA-Flex) scan. The T2-
weighted sequence shows a good contrast between the colon anatomy and surrounding 
tissue (e.g. abdominal fat), and in the current analysis method it is used for 
segmentation of colon volume and assess the amount of water in the colonic content. 
The segmented volume includes both content and luminal gas. The LAVA-Flex 
sequence shows good contrast between solid colonic content and luminal gas. In the 
current analysis method, it is used for segmentation of fecal volume. In Paper III, it 
was also proposed to include the LAVA-Flex images for analysis of water in the 
colonic content, however the T2-weighted images proved to perform better, why the 
LAVA-Flex measured stool dryness is not presented in this thesis. Detailed 
description of MRI parameters is shown in Paper III.  
  
Step 1 Step 2 Step 3 Step 4
MRI Segmentation Volume quantification Content analysis
Intensity
Co
un
t
Figure 19. The four analysis steps included for MRI-based analysis of colonic fecal content 
and stool dryness.  
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Step 2: Segmentation  
Colonic volumes were subtracted from the T2-weighted images using a segmentation 
platform which allows the user to draw a line around the colon and divide the volume 
in colonic segments (Figure 20). Segments are separated at the hepatic flexure, the 
splenic flexure and at the left anterior iliac spine, which divide the colonic volume 
into the four segments: 1) cecum and ascending colon, 2) transverse colon, 3) 
descending colon, and 4) rectosigmoid. A trained observer uses approximately 20-30 
minutes in the manual segmentation process depending on image quality and 
individual anatomy. 
Alyami et al., 2015.89 
Step 3: Volume quantification  
After manual segmentation on the two MRI image series, the software classifies all 
voxels according to their signal intensity using the k-means clustering algorithm 
initiated with three random cluster centers. Non-colon voxels (on T2-weighted 
images) and non-colon content voxels (on LAVA-Flex images) are discarded by the 
algorithm (Figure 21). Wrongfully classified areas can afterwards be corrected by the 
observer. Reliability of the colonic fecal volumes were assessed by comparing 
measurements performed at the two baseline days in trial 3 (Paper III). 
  
T2-weighted images 
show  colonic volume
LAVA-Flex images 
show colonic content
Figure 20. Schematic representation of the manual segmentation of colonic segments on T2-
weighted images (left) and LAVA-Flex images (right). Colonic segments are separated by the 
hepatic flexure, the splenic flexure and at the left anterior iliac spline. Illustration inspired by  
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Step 4: Analysis of colonic content 
The median T2-weighted signal intensity of the segmented colonic content was used 
as a simple measure of colonic stool dryness. On the T2-weighted images, water is 
represented as very bright (high signal intensity), while dry feces were hypothesized 
to be represented as dark (low signal intensity). This hypothesis was tested in a simple 
setup, where the signal intensity of different mixes of oatmeal and amount of water 
was estimated using the same scanning sequence (Paper III). The luminal gas is 
however darker than feces, why the volume of gas pockets need to be subtracted 
before analysis of the MRI signal intensities in order to avoid introducing a bias in 
results. The difference in volume between colonic content (shown in LAVA-Flex 
images) and colonic volume (shown in T2-weighted images) is equal to the luminal 
gas volume.90 Voxels representing gas volume in the T2-weighted images were then 
discarded based upon analysis of signal intensity, and the median T2-weighted signal 
intensity was computed and used as a proxy for colonic stool dryness (Figure 22).  
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Figure 22. Analysis of colonic content. A) LAVA-Flex image showing area in the rectosigmoid 
colon with luminal gas. B) T2-weighted image showing area in the rectosigmoid colon with 
luminal gas. C) 3D-model of the segmented colonic volume and content. Arrows point to 
luminal gas. D) Histogram representation of segmented colonic content on T2-weighted images 
in one dataset. High values indicate more water content, where ascending colon content contain 
most water (yellow) and rectosigmoid colon contains least water (blue). 
Figure 21. Classification of colonic volume and colonic content using a k-means clustering 
algorithm. Ascending colon is yellow, descending colon is green, and sigmoid colon is blue. A) 
Manual drawn region on a T2-weighted image. B) Classified colonic volume on a T2-weighted 
image. C) Manual drawn region on a LAVA-Flex image. D) Classified colonic content on a 
LAVA-Flex image.  
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CHAPTER 5. KEY RESULTS 
The key results to answer the six aims are presented in this chapter. Detailed results 
are reported in the papers. An overview of the main results is illustrated in Figure 23. 
5.1. AIM 1 
Aim: To develop, test reliability and validate a method to measure colonic length 
using the 3D-Transit system (Paper I). 
Key results: 
- Colonic length measured with 3D-Transit was 95 (75-153) cm and was not 
different from MRI derived measures (P = 0.15). 
- The coefficient of variation (CV) between MRI and 3D-Transit measured 
colonic length was 7.8%. 
Interpretation  
It was possible to develop a method to measure colonic length using the 3D-Transit 
system. Colon length estimated with the system was validated against known colon 
anatomy derived using MRI.  
 
 
Decreased detailed colonic motility 
during oxycodone treatment
Increased fecal volume during  
oxycodone treatment
Increased detailed colonic motility  
during naloxegol treatment
Increased stool dryness during  
oxycodone treatment
Aim 1
Aim 2
Aim 3
Aim 4
Aim 6Aim 5
Colonic length reliable between days
Colonic length not different from MRI
Increased fast motility in CD
Detailed colonic motility described in HV
Fecal volume reliable between days
Fecal dryness reliable between days
Oxycodone 
vs. placebo
Naloxegol+oxycodone 
vs. placebo+oxycodone
Decreased transit times during 
naloxegol treatment
Validation of 
methods
Figure 23: Overview on key results included from the four papers (I-IV). Abbreviations: CD, 
patients with chronic diarrhea; HV, healthy volunteers 
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5.2. AIM 2 
Aim: To develop, test reliability and validate a method to measure detailed colonic 
motility using the 3D-Transit system (Paper II). 
Key results: 
- Total colonic transit and motility measures showed high variation between 
measurements performed on two consecutive days with a coefficient of 
variation ranging from 31-61%, 
- Propulsive velocity peaked at 0.5 cm/min (retrograde or antegrade) and at 50 
cm/min (antegrade). 
- The capsule progressed faster during the day than at night (5.9 cm/h vs. 0.8 
cm/h; P<0.01).  
- Capsule velocity was faster in patients with diarrhea compared to healthy 
volunteers (20.4 cm/h vs. 4.4 cm/h; P<0.01). 
Interpretation  
It was possible to develop a method to measure colonic motility. The length of the 
colon was used as a guidance for tracking 3D-Transit capsule movement length, 
velocity and direction. Measurements of colonic motility in healthy volunteers 
showed that the capsule was moved in five different types of movements of varying 
length, velocity and direction. Patients with diarrhea had an faster movement pattern. 
5.3. AIM 3 
Aim: To develop and test reliability of a method to measure colonic fecal volume and 
colonic fecal dryness using MRI (Paper III). 
Key results: 
- Segmental and colonic fecal volumes showed moderate to good reliability 
between week-to-week measurements (all P < 0.005, all ICC > 0.52). 
- Segmental and colonic stool dryness assessed with T2-weighted MRI 
showed poor reliability between week-to-week measurements of the 
ascending-, descending-, and sigmoid colon (all P < 0.01); measurement of 
the transverse- and total colon showed moderate to strong reliability (both 
P<0.002). 
Interpretation  
It was possible to develop a method to estimate colonic fecal volume and stool 
dryness. Measures of colonic fecal volume was consistent between measurements 
separated by weeks, and variation can partly be explained by physiological factors 
and diets.  
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5.4. AIM 4 
Aim: To evaluate how oxycodone treatment, compared to placebo, affects colonic 
fecal volume and colonic fecal dryness (Paper III). 
Key results: 
- Oxycodone increased total colonic fecal volume (P = 0.001) with largest 
volume increase during treatment observed in the ascending colon (P = 
0.004). 
- Colonic stool dryness assessed with T2-weighted images increased during 
oxycodone treatment compared to placebo (P = 0.002) with highest 
difference in the descending colon (P = 0.03). 
Interpretation  
Five days of oxycodone treatment increases colonic fecal volumes and reduces the 
amount of water in the colonic content. 
5.5. AIM 5 
Aim: To evaluate how oxycodone treatment, compared to placebo, affects detailed 
colonic motility (Paper IV). 
Key results: 
- Colonic transit time increased during oxycodone treatment compared to 
placebo (P < 0.01); with slowest transit in the ascending colon (P = 0.03).  
- Oxycodone treatment impaired the number of long fast antegrade 
movements (P < 0.001), with most difference in the descending colon (P < 
0.04). 
- Oxycodone increased the number of slow antegrade movements compared 
to placebo (P = 0.002). 
Interpretation  
Oxycodone treatment slows colonic transit, mostly caused by a reduced number of the 
long fast antegrade movements (mass movements), and an increased number of 
slower movements.  
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5.6. AIM 6 
Aim: To evaluate how the opioid antagonist naloxegol co-administered with 
oxycodone, compared to placebo co-administered with oxycodone, affects detailed 
colonic motility (Paper IV). 
Key results: 
- Colonic transit time was faster during oxycodone+naloxegol compared to 
oxycodone+placebo (P = 0.049); with most difference seen in the sigmoid 
colon (P < 0.001). 
- The number of slow antegrade movements was higher during 
oxycodone+placebo than during oxycodone+naloxegol (P = 0.03). 
- More distance was covered in fast antegrade movements during 
oxycodone+naloxegol than during oxycodone+placebo (P = 0.04). 
Interpretation  
Naloxegol (combined with oxycodone) returns transit time and colonic motor activity 
towards normality, but not entirely. 
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CHAPTER 6. DISCUSSION 
The overall objective of the present PhD thesis was to develop and apply methods to 
assess the effect of opioids on colonic motility, fecal volume and fecal dryness, and 
to assess the effect of opioid antagonists co-administered with opioids on colonic 
motility. The discussion is divided in two parts. The first part focuses on the 
methodological considerations of the applied methods, after which the advantages and 
drawbacks of the experimental settings will be discussed. 
6.1. METHODOLOGICAL CONSIDERATIONS 
6.1.1. 3D-TRANSIT 
The 3D-Transit system offers many possibilities in regarding to analysis of GI 
function and motility and provide information that cannot be obtained with other 
measurement techniques. The system tracks electromagnetic capsules through the GI 
passage and allows for assessment of capsule movement in real time with a high 
temporal resolution. The ‘novelty’ of the system is that it accurately describes intra-
luminal movement (at least of an indigestible capsule), which is the functional 
consequence of contractile events. The first schematic representations of colonic 
motor patterns were obtained in the studies by Ritchie in the 1960’s using radiological 
methods.91,92 A lot have happened since then in regards to safe measurement 
techniques. Now we can describe contractile activity using the WMC, but 
unfortunately, this capsule cannot be accurately tracked through colonic transit. 
Together with high-resolution colonic manometry, which has added most of the 
current knowledge of colonic motor patterns, the 3D-Transit system is a 
complementary assessment tool enabling insight into the various colonic movements, 
despite the limitations of the system. In the current thesis, the 3D-Transit system was 
used to analyze both colonic length and motor patterns including segmental colonic 
transit times. Algorithms, parameters and settings were inspired by the study by Hiroz 
et al., 2009.36 A new analysis platform was implemented to clean data and classify 
motor patterns.  
Colonic length  
Estimations of colonic length were performed as a step on the way to describe colonic 
motility patterns. The proposed method was found to produce overall good reliability 
between estimations performed on two consecutive days, and between 3D-Transit and 
MRI-derived measurements.71 The estimations in the ascending colon proved to be 
most problematic, as in some recordings, the capsule either stayed in the cecum for a 
long period, or it progressed fast after it entered the colon and would never fall into 
the cecum pouch. The anatomy of the ascending colon shown on the MRI images 
(used for comparison) also differed, which may be caused by contractions and 
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relaxations that affects colonic length,43 and diets and bowel movements also have an 
impact on the volume of the colon.78,90 Colonic length is not a clinical used parameter, 
why it can be difficult to validate the method against any gold standard. Several 
methods to measure colonic length have been proposed e.g. using swallowed tubes or 
measure the inserted length of a colonoscope during colonoscopy.21,93 These 
approaches may however underestimate true colonic length due to the confounding 
‘concertina’ effect when inserting the catheter.94 Imaging techniques can be used 
without this limitation (depending on the type of bowel preparation), why MRI was 
chosen as validation method in this thesis. Measurements of colonic length alone have 
also been performed using a manual approach by drawing on abdominal radiographs 
after bowel preparation with rectal injected barium.95 The method used to extract 
colonic length from MRI images was, however, not a validated method, which of 
course limits the validity of findings (Paper I). The same analysis approach was used 
for all images, and due to the good contrast between colon and surrounding tissue in 
the T2-weighted images, it was easy to inspect the centerline produced by the 
algorithm (and redo if failed). Measures of colonic length may have clinical 
applications as an elongated colon is associated with prolonged transit in both children 
and adults.96,97 The 3D-Transit system is however an unpractical approach to measure 
colonic length, while imaging of the colon can be performed much faster (20 seconds 
MRI vs. approximately 24 hours normal GI transit time), and the imaging data is easier 
and faster to interpret. The length measure proposed in this thesis is used in the further 
progress to calculate capsule movements; hence, it will be calculated as part of the 
full colonic motility analysis, and estimation of the length alone does not make much 
practical sense.  
Detailed colonic motility 
There exist only few other methods to investigate colonic motility, where HRM has 
introduced much of the current knowledge on colonic motor patterns in health and GI 
disease.32,33 HRM measures luminal pressure waves unlike the 3D-Transit system that 
provides insight into how luminal content progresses (and stands still) through the 
colonic transit. Two recordings of similar transit time can have very different 
progression patterns as shown in Paper II, where one pattern shows slow progression 
through the colon, and another shows that capsule progression is mainly caused by 
two very long and fast mass movements.20 This information cannot be obtained with 
other motility capsules. Motility capsule systems do, however, include other 
limitations, where one of the most significant is the very high variation in colonic 
motility that is difficult to interpret using a single capsule. The anatomical location of 
radiopaque markers often differs between colonic segments, why it is normal to track 
10 markers during an examination, and calculate a colonic transit time based on a 
scoring system.98 The 3D-Transit system offers possibility to track 3 capsules 
simultaneously, although interpretation of results may be more complicated. Paper II 
included analysis of healthy volunteers that ingested three capsules over two days 
(morning day 1, evening day 1, and morning day 2). Variation in colonic motility 
during normal days, even with standardized diets was very high. In fact, total colonic 
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transit and motility measurements in the healthy volunteers all had coefficient of 
variation ranging from 31-61%, which must be regarded as high intra-subject 
variation.20 Colonic activity was higher during daytime compared to nighttime. A 
peak in colonic activity was also observed during mornings, however, it was not 
possible to show a significant effect of meals, which has been shown previously.32,36,37 
Colonic transit times was longer in recordings, where the capsule was ingested in the 
evening.20 This is not surprising as defecation is normally performed in the mornings, 
and the evening-ingested capsule would often be located in the proximal colon the 
following morning, why it stayed in the colon and awaited toilet visit next morning 
36 hours after ingestion. This specific finding was also reported in a WMC study of 
215 healthy volunteers made by Wang et al.72 They discovered that the WMC was 
often expelled in the mornings, and when it was not, the capsule was often expelled 
24 hours later. This makes a bimodal distribution in normal transit times with 1 day 
between peaks. The capsule would most likely await expulsion in the sigmoid or 
rectum, which cannot be known using the WMC, but easily investigated using the 3D-
Transit system.  
     Motility analysis in healthy volunteers showed that the capsule traversed both at 
fast and slow velocities, at differing length and mostly antegrade, but also retrograde. 
The velocity of capsule movements in especially the long fast antegrade movements 
could be compared to the motor patterns described using HRM. Dinning et al. 
examined 10 healthy volunteers with HRM, and they found that high-amplitude 
propagating sequences (HAPS) propagated a mean 33±12 cm (range 11-50 cm), with 
a mean velocity of 0.4±0.1 cm/s.32 Furthermore, they reported another motor pattern 
called ‘long single propagating motor pattern’ with even faster progression velocity 
than HAPS. These movements propagated a mean 41±8 cm, with a mean velocity of 
1.8±1.2 cm/s. The healthy 3D-Transit recordings reported in Paper II, did also include 
movements at high velocity, where most fast antegrade activity displaced the capsule 
at approximately 0.2-2.5 cm/s),20 which implies that our classification most likely 
include more than one previous identified motor pattern. The 3D-Transit capsules do 
not include a pressure sensor, why it cannot be determined if the classified long and 
fast movements have high amplitude pressure events like in the HRM recorded HAPS. 
Future improvement of analysis may allow the system to distinguish between more 
types of motor patterns as reported by Dinning and colleagues, but a validation study 
between methods is needed before further conclusions on the relation between motor 
patterns can be made. 
     Motility analysis in healthy volunteers during oxycodone treatment (Paper IV) 
showed that colonic transit time was increased due to reduced efficacy and number of 
long fast antegrade movements that contributed to a slower capsule progression 
velocity. Moreover, the oxycodone treatment increased the number of short and slow 
antegrade movements and did not affect retrograde activity. This means that the 
opioids slowed propulsion but did not cause any dyscoordinated peristalsis; at least 
not enough to be found with the current analysis methods. Dyscoordinated peristalsis 
is however believed to contribute to the pathophysiology underlying OIC,99 why it 
was also hypothesized that oxycodone would cause this phenomenon. Naloxegol in 
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co-administration with oxycodone did not normalize colonic transit entirely nor did it 
return the number of long fast movements to the levels reported in the placebo-arm in 
Paper IV and the healthy population in Paper II. However, when naloxegol was 
combined with oxycodone, transit time was significantly reduced, especially in the 
rectosigmoid colon, compared to oxycodone treatment alone. This may be due to the 
change in motor patterns between the two treatments, where the capsule was moved 
significantly longer in the short fast movements during naloxegol and there was less 
of the slow antegrade movements that was found to be caused by oxycodone treatment 
(Paper IV). The increase in fast movements during naloxegol was mainly in the distal 
colon, which could coincide with the decreased transit time in the rectosigmoid. 
     Previous, the system has mostly been used to report regional transit times;10,80,81 
however, manual assessments of ‘pansegmental colonic movements’ have also been 
included in a study by Gregersen et al.79 Furthermore, analysis of GI motility in 
healthy volunteers during sleep has also been reported in a study by Haase et al. using 
another approach than the one used in the current thesis.86 They assessed gastric 
contraction frequency using power spectral analysis, and estimated small bowel and 
colonic propagating sequences (like the ones presented in the current thesis) and 
colonic activity for short movement periods. Their approach inspired the analysis 
methods implemented to estimate colonic motility in the current thesis, and the 
authors in that study also contributed to Paper I, II and IV. The study by Hiroz et al., 
2009 compared colonic transit times measured with the previous version of the 
motility capsule system with standard radiopaque markers,36 where about 60% of the 
markers were clustered in the zone of the capsule. Worsøe et al. measured gastric and 
small bowel transit times with the PillCam and compared with the previous capsule 
system and found a good agreement between measurements.82 Total transit time 
measured with the current system was in the study by Haase et al. compared with 
radiopaque markers, and they found a positive correlation (Spearman’s rho = 0.7).70 
However, it is also important to test how results vary among different observers. 
Haase et al. also found that the inter-rater reliability of assessed transit times was very 
good, although the observers helped each other during analysis, and they were not 
blinded to previous analysis of the same data. Kalsi et al. tested both intra- and inter-
rater reliability in a blinded setup, with three observers with varying experience in 
analysis.87 They found that the level of  experience had an impact on results, and the 
observer with the lowest level of experience reported regional transit times with very 
low reliability. All colonic motility measurements presented in this thesis have been 
performed by a single trained observer. All steps in the analysis may potentially 
impact the reported results, why reliability studies of the proposed colonic motility 
measurements are warranted. It would also be very interesting to compare the new 
motility measures with motor patterns obtained during simultaneous recordings with 
high-resolution colonic manometry. 
CHAPTER 6. DISCUSSION 
 
47 
6.1.2. MAGNETIC RESONANCE IMAGING 
Fecal volume and stool dryness data were obtained with MRI to provide additional 
insight into the functional state of the colon. The 3D-Transit capsule offers measures 
of motor function through estimations of motility and transit times, while MRI offers 
indirect measures of gut secretion and absorption. However, a single measurement of 
volume does not provide much useful information, because individual measures of 
colonic volume have high variation,78 which makes it difficult to determine abnormal 
values. The measure is more useful if performed several times during a time period to 
e.g. assess treatment effects (Paper IV). Insight into the luminal content and its water 
amount would provide another useful layer of information. In the current thesis, 
analysis methods to extract this information was proposed. In Paper III, MRI was used 
to detect the effect of oxycodone on colonic fecal volume and stool dryness. The used 
MRI methods allow for a more detailed description of colonic physiology than colonic 
volume alone. The method can detect fecal composition, and dry feces may itself lead 
to constipation symptoms. 
Colonic fecal volume and stool dryness during treatment with 
oxycodone and naloxegol 
A five-day treatment of oxycodone increased total colonic fecal volume with the 
highest increase in the proximal colon and surprisingly no change in the rectosigmoid. 
The 3D-Transit system detected increased transit times during the oxycodone 
treatment (most pronounced proximal), why the stable fecal volume in the distal colon 
may be explained by the increased time of passive fluid absorption during colonic 
passage. This phenomenon is further supported by the measure of stool dryness that 
detected a change in chyme signal intensity between treatments. Lastly, the subjects 
also reported their stool to be drier and harder during oxycodone treatment (not part 
of this thesis, but reported in a study by Nilsson et al.).76 Investigations of evacuation 
function would furthermore be very useful to help us understand why subjects 
accumulated more feces in the colon during oxycodone treatment compared to 
placebo. Although, no change was observed in the sigmoid colon, why it can only be 
speculated how much the mechano-sensitive reflex (that promotes the urge of 
defecation) is affected by the treatment. Morphine has although previously been found 
to increase the elicitation threshold for the recto-anal inhibitory reflex.100 The 
accumulation of feces in the proximal colon during oxycodone treatment may be 
further explained by the insight into colonic motility obtained with the 3D-Transit 
capsule. The system detects long propagating movements that include the powerful 
HAPSs (normally detected using HRM). These are believed to originate in the 
ascending colon and propagate through most of the colon a few times each day.32 
During oxycodone treatment, much less long fast movements were detected, which 
could explain the increase in fecal volume in the ascending colon, when the long 
movements do not propagate the feces as often due to the opioid-induced GI 
symptoms. This is also the case in slow transit constipation,33 why the 
pathophysiology underlying OIC may mirror other GI disease. Variation between 
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volumes and stool dryness of colonic fecal content measured at the baseline days in 
Paper III (separated by a mean of 52 days) could partly be explained by diets and 
normal variation.90 Measurements might have shown higher reliability if they were 
performed on two following days and if subjects were on standardized diets through 
the study. Analysis was performed by a single observer, however the segmentation 
method has previously been tested with two observers with low inter-observer 
variation, why further testing of the methods was not performed.78 A recent study by 
Major et al., 2018 also used MRI to assess water content in the colon content, and 
their results correlated well with the actual amount of water in feces (using a freeze 
drying procedure).101 It is a great limitation of the method applied in Paper III that no 
actual validation against known water amount was made. The method did show an 
effect of the oxycodone treatment on the appearance of the luminal content; however, 
it may be speculated if this change is due to reduced amount of water as it may as well 
be caused by increased fermentation or something entirely else. 
6.2. EXPERIMENTAL SETTINGS 
Pharmacological treatments 
The administered treatment doses of oxycodone in trial 3 were chosen based upon 
what was hypothesized to induce OIC and still be ethically justifiable. Chronic pain 
patients may experience other opioid-induced symptoms due to longer treatments or 
higher doses, however the included healthy volunteers in trial 3 doubled colonic 
transit times (Paper IV), increased colonic fecal volume (Paper III), reported increased 
GI symptoms (not part of the current thesis, but investigated in a study by Nilsson et 
al.).76 In trial 3, the 3D-Transit capsule was ingested before oxycodone was 
administered, why the opioid-induced GI symptoms would not be present in the first 
part of recordings. The colonic recordings included in this thesis may however not be 
affected of the ingestion time of the capsule, but it influenced the transit times 
recorded in the stomach.10 In order to avoid this effect in trial 4, the capsule ingestion 
time was changed to be one day after first treatment dose. Furthermore, the oxycodone 
dose was increased compared to trial 3 resulting in an increased transit time. The dose 
of naloxegol in trial 4 was chosen as the recommended dose to treat OIC, however it 
may have been too low when administered in opioid-naïve healthy volunteers. Hence, 
in a recent healthy volunteer study by Halawi et al., 2018 it was found that the same 
dose (25 mg naloxegol) did not normalize transit times during treatment with 
codeine.102 Furthermore, Van Malderan et al. showed that chronic opioid-treated 
patients needed a lower dose of naloxegol to reduce GI symptoms than opioid-naïve 
healthy volunteers.103 Therefore, the dose of naloxegol used in trial 4 may lead to an 
underestimated treatment effect.  
Experimental OIBD models in healthy volunteers 
In trial 3 and 4 the effect of pharmacological treatments on the GI tract was studied in 
healthy volunteers. The included number of subjects and duration of treatments were 
limited to what was ethical reasonable. Patients with OIC have often been treated with 
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opioids for a long period, why the chosen study design may not reflect clinical OIC. 
Healthy volunteers do, however, not have co-morbidities, psychiatric disorders or use 
concomitant medication.76 Hence, the confounding factors are limited and it may be 
easier to identify underlying mechanisms involved in the pathophysiology of OIC. 
The findings in this thesis may have shown even higher variation if examinations were 
performed in a heterogeneous patient group instead of the investigated population of 
healthy young males. 
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CHAPTER 7. CONCLUSION 
This PhD thesis had six aims investigated in four clinical trials. We can conclude that 
it was possible to develop reliable methods to measure colonic length and colonic 
motility using the 3D-Transit system (Aims 1 and 2). Furthermore, MRI-methods to 
investigate colonic fecal volume and stool dryness were also tested to be reliable 
within normal physiological variation (Aim 3). Five-days treatment with oxycodone 
lead to constipation-related symptoms in healthy volunteers including increased 
colonic fecal volume and stool dryness (Aim 4). During oxycodone treatment, colonic 
motility decreased shown by increased colonic transit times and changed motor 
patterns, mainly caused by decreased length and velocity of contractile movements 
(Aim 5). Co-administration of naloxegol during oxycodone treatment reversed 
colonic motility towards normality in regards of transit times and fast contractile 
activity (Aim 6).  
All included measures were sensitive to detect GI changes after experimentally-
induced OIC. Especially, the 3D-Transit system offers novel and interesting insights 
into GI motility that cannot be obtained with other ambulatory measurement 
techniques. MRI measurements of fecal volume and stool dryness are easily obtained, 
and they proved useful in investigating treatment effects. Moreover, the methods are 
faster and less observer dependent than manual investigations. 
7.1. FUTURE PERSPECTIVES & CLINICAL IMPLICATIONS 
The analysis framework proposed in this PhD thesis provide useful information for 
future improvement and development of methods to asses GI function and symptoms 
related to OIC or other GI diseases. The thesis was limited to investigate physiology 
in the colon, however the 3D-Transit may have potential for detailed investigations of 
the stomach and small bowel. Currently, an analysis method for assessment of 
contractile activity in the stomach is being developed (Sutter et al., unpublished). This 
method may be particularly interesting in patients with gastroparesis, where transit 
time can be assisted by motility measures. Furthermore, the 3D-Transit system is at 
this time being used to investigate different patient groups including patients with 
diabetes and constipation. It will be interesting to see, if detailed information of 
colonic motility can help in treatment of GI symptoms. MRI has recently been used 
in pan-intestinal studies of GI motility as shown in the study by Khalaf et al., 2018.104 
When designing a new experimental study that includes investigation of the GI tract, 
it should be investigated if additional MRI measurements could be included in the 
protocol. Refinement and further validation of the MRI method to assess colonic water 
content would add more insights into the colonic absorption and secretion of fluids 
and how they are affected by opioid treatment. Additionally, inclusion of an imaging-
based method to assess the recto-anal inhibitory reflex would provide insight into 
another important aspect of the pathophysiology underlying OIC.
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